Pain pharmacotherapy in patients with inflammatory arthritis and concurrent cardiovascular or renal disease: A Cochrane systematic review

Journal of Rheumatology

Volumn 39, Issue SUPPL. 90, 2012, Pages 81-84

  Marks, Jonathan L ^a   Van Der Heijde, Désirée M ^b   Colebatch, Alexandra N ^c   Buchbinder, Rachelle ^d   Edwards, Christopher J ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c YEOVIL DISTRICT HOSPITAL   (United Kingdom)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Ankylosing spondylitis; Cardiovascular; Pain rheumatoid arthritis; Psoriatic arthritis; Renal; Systematic review

Indexed keywords

DICLOFENAC; ETORICOXIB; ANALGESIC AGENT; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANALGESIA; ARTHRITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFLAMMATORY ARTHRITIS; KIDNEY DISEASE; OSTEOARTHRITIS; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CLINICAL PRACTICE; COMPARATIVE STUDY; METHODOLOGY; PATHOPHYSIOLOGY;

ANALGESICS; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; PAIN; PAIN MANAGEMENT; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84865843775     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120347     Document Type: Review

References (20)

1. Whittle SL, Colebatch AN, Buchbinder R, Edwards CJ, Adams K, Englbrecht M, et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: Integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology 2012 Mar 24. [Epub ahead of print]
2. Marks JL, Colebatch AN, Buchbinder R, Edwards CJ. Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity. Cochrane Database Syst Rev 2011;10:CD008952.
3. Marks JL, Colebatch AN, Buchbinder R, Edwards CJ. Pain management for rheumatoid arthritis and cardiovascular or renal co-morbidity (Protocol). Cochrane Database Syst Rev 2011;1:CD008952.
4. Bergman MJ. Social and economic impact of inflammatory arthritis. Postgrad Med 2006;Spec No:5-11.
5. Taylor P, Alvaro-Gracia J, Johnstone R, Gomez-Reino J, Eberhardt E, Wolfe F, et al. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res 2010;38:1213-24.
6. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
7. Kearney P, Baigent C, Godwin J, Halls H, Emberson J, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8.
8. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63.
9. Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, Raggi P, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006;8:R186.
10. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: Relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005;52:3045-53.
11. O'Connor D, Green S, Higgins JPT, editors. Ch 5. Defining the review question and developing criteria for including studies. In: Higgins JPT, Green S, editors. Cochrane handbook of systematic reviews of interventions. Version 5.0.1. The Cochrane Collaboration; 2008.
12. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research an effectiveness. CRD's guidance for those carrying out or commissioning reviews. York: Centre for Reviews and Dissemination, University of York; 2001. Report No. 4.
13. Higgins J, Altman D. Assessing risk of bias in included studies. Ch. 8. In: Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration; 2008.
14. EPOC data collection checklist. [Internet. Accessed May 2, 2012.] Available from: http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/ datacollectionchecklist.pdf
15. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. [Internet. Accessed May 2, 2012.] Available from: http://www.ohri.ca/programs/clinical-epidemiology/oxford.htm
16. Bolten WW. Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2006;65:7-13.
17. Farkouh ME, Greenbery BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009;103:1227-37.
18. Trelle S, Reichenback D, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta-analysis. BMJ 2011;342:c7086.
19. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet 2006;368:1771-81.
20. Peters MJL, Symmons DPM, McCarey D. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.